Literature DB >> 20662706

Reversible posterior leukoencephalopathy syndrome in a patient of FSGS with heavy proteinuria.

Zahid Nabi1, Lutfi Al Korbi, Mohamed Ghailani, Quaid Nadri, Mohamed Abdelsalam, Mamdouh Al Baqumi.   

Abstract

Reversible posterior leukoencephalopathy syndrome (RPLS) is a neurological syndrome characterized by headache, seizures, and visual loss, often associated with an abrupt increase in blood pressure. It was first described by Hinchey and colleagues in 1996 when they described a case series. RPLS has been described in number of medical conditions, renal dysfunction being one of them. Prompt diagnosis and therapy with antihypertensives, anticonvulsants, removal of any offending medication, and treatment of associated disorder are essential because early treatment might prevent progression to irreversible brain damage. Here, we report a case of young man with focal segmental glomerulosclerosis (FSGS) and heavy proteinuria, who developed classical, clinical, and neurological features of RPLS with complete recovery.

Entities:  

Mesh:

Year:  2010        PMID: 20662706     DOI: 10.3109/0886022X.2010.494794

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  3 in total

1.  Posterior reversible encephalopathy syndrome in malignant hypertension secondary to focal segmental glomerulosclerosis.

Authors:  Hafez Mohammad Ammar Abdullah; Waqas Ullah; Ejaz Ahmad; Faiz Anwer
Journal:  BMJ Case Rep       Date:  2016-08-17

2.  Posterior reversible encephalopathy syndrome in a woman with focal segmental glomerulosclerosis.

Authors:  Mudit Chowdhary; Ahmad A Kabbani; Devon Tobey; Thomas D Hope
Journal:  Neuropsychiatr Dis Treat       Date:  2015-04-21       Impact factor: 2.570

3.  Nephrotic Syndrome and Atypical Posterior Reversible Encephalopathy Syndrome in a Patient with Parkinson's Disease.

Authors:  Ryo Tokimura; Eiichi Ito; Yoshihiro Sugiura; Yoshikazu Ugawa
Journal:  Intern Med       Date:  2021-12-18       Impact factor: 1.282

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.